Get the Stockscreener App
5.72
2.89%
-0.17
After Hours:
5.70
-0.02
-0.35%
Ardelyx Inc stock is traded at $5.72, with a volume of 3.87M.
It is down -2.89% in the last 24 hours and down -16.13% over the past month.
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
See More
Previous Close:
$5.89
Open:
$5.84
24h Volume:
3.87M
Relative Volume:
1.25
Market Cap:
$1.35B
Revenue:
$159.11M
Net Income/Loss:
$-65.81M
P/E Ratio:
-47.67
EPS:
-0.12
Net Cash Flow:
$-81.12M
1W Performance:
-4.83%
1M Performance:
-16.13%
6M Performance:
-34.40%
1Y Performance:
+42.29%
1-Day Range:
$5.65
$5.90
1-Week Range:
$5.65
$6.44
52-Week Range:
$3.43
$10.13
Ardelyx Inc Stock (ARDX) Company Profile
Name
Ardelyx Inc
Sector
Industry
Phone
510-745-7047
Address
34175 ARDENWOOD BLVD., FREMONT, CA
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-02-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Apr-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-18-23 | Initiated | Raymond James | Strong Buy |
| Sep-07-23 | Initiated | H.C. Wainwright | Buy |
| Aug-25-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-03-23 | Upgrade | Wedbush | Neutral → Outperform |
| Nov-17-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-01-21 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Oct-14-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-21-21 | Downgrade | Jefferies | Buy → Hold |
| Jul-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-20-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-23-21 | Initiated | Wedbush | Outperform |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-20-20 | Resumed | Citigroup | Buy |
| Feb-18-20 | Resumed | Jefferies | Buy |
| Feb-12-20 | Initiated | Citigroup | Buy |
| Feb-10-20 | Initiated | Cowen | Outperform |
| Apr-08-19 | Initiated | Piper Jaffray | Overweight |
| Aug-24-18 | Initiated | Jefferies | Buy |
| Mar-19-18 | Resumed | Leerink Partners | Outperform |
| Nov-29-17 | Reiterated | Citigroup | Buy |
| Nov-22-17 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-17-17 | Resumed | Leerink Partners | Outperform |
| Mar-31-16 | Initiated | Ladenburg Thalmann | Buy |
| Mar-09-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-03-16 | Initiated | Citigroup | Buy |
View All
Ardelyx Inc Stock (ARDX) Latest News
Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference - ForexTV.com
What is Wedbush’s Forecast for Ardelyx FY2026 Earnings? - Defense World
ARDX Investors Have Opportunity to Lead Ardelyx, Inc.Securities Fraud Lawsuit with the Schall Law Firm - GuruFocus.com
ARDX LAWSUIT ALERT: Levi & Korsinsky Notifies Ardelyx, Inc. Inve - GuruFocus.com
Citigroup Has Lowered Expectations for Ardelyx (NASDAQ:ARDX) Stock Price - MarketBeat
Wedbush Research Analysts Cut Earnings Estimates for Ardelyx - MarketBeat
Ardelyx, Inc. (NASDAQ:ARDX) Q3 2024 Earnings Call Transcript - MSN
Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts - Simply Wall St
Ardelyx (NASDAQ:ARDX) Stock Price Up 7.3% – Here’s Why - Defense World
Allspring Global Investments Holdings LLC Sells 19,212 Shares of Ardelyx, Inc. (NASDAQ:ARDX) - Defense World
Lost Money on Ardelyx, Inc.(ARDX)? Join Class Action Suit Seekin - GuruFocus.com
Ardelyx Third Quarter 2024 Earnings: US$0.003 loss per share (vs US$0.03 profit in 3Q 2023) - Yahoo Finance
Compared to Estimates, Ardelyx (ARDX) Q3 Earnings: A Look at Key Metrics - MSN
Ardelyx (NASDAQ:ARDX) Earns "Buy" Rating from HC Wainwright - MarketBeat
Earnings call: Ardelyx reports solid growth amid Medicare challenges - Investing.com
Earnings call: Ardelyx reports solid growth amid Medicare challenges By Investing.com - Investing.com Canada
Ardelyx (NASDAQ:ARDX) Shares Up 7.3%Should You Buy? - MarketBeat
Ardelyx Target of Unusually High Options Trading (NASDAQ:ARDX) - MarketBeat
Ardelyx CEO Michael Raab sells $147,740 in stock By Investing.com - Investing.com Australia
Ardelyx Inc (ARDX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Growth Amidst ... - Yahoo Finance
Ardelyx CEO Michael Raab sells $147,740 in company stock By Investing.com - Investing.com Canada
Ardelyx Reports Robust Q3 2024 Revenue Growth - TipRanks
Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update - ForexTV.com
Ardelyx reports Q3 EPS 0c, consensus (5c) - TipRanks
Ardelyx Beats Q3 Sales Estimates, Shares Climb - MSN
Ardelyx: Q3 Earnings Snapshot - Houston Chronicle
ARDXArdelyx, Inc. Latest Stock News & Market Updates - StockTitan
Ardelyx (ARDX) Reports Break-Even Earnings for Q3 - Yahoo Finance
Ardelyx options imply 14.6% move in share price post-earnings - TipRanks
Ardelyx, Inc. Sued for Securities Law ViolationsInvestors Sho - GuruFocus.com
Ardelyx CEO Michael Raab sells $147,740 in stock - Investing.com India
Ardelyx CEO Michael Raab sells $147,740 in company stock - Investing.com
Michael Raab Sells 25,000 Shares of Ardelyx, Inc. (NASDAQ:ARDX) Stock - MarketBeat
ARDX LAWSUIT ALERT: The Gross Law Firm Notifies Ardelyx, Inc. In - GuruFocus.com
Ardelyx's Earnings Outlook - Benzinga
Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology’s (ACG) Annual Meeting - ForexTV.com
Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American - The Bakersfield Californian
(ARDX) Trading Report - Stock Traders Daily
Ardelyx reports positive XPHOZAH trial results at ASN Kidney Week - Investing.com India
Ardelyx announces presentation of Xphozah data at Kidney Week - TipRanks
Ardelyx reports positive XPHOZAH trial results at ASN Kidney Week By Investing.com - Investing.com South Africa
Ardelyx Shares Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) at the American Society of Nephrology’s Kidney Week - StockTitan
Earnings Preview: Ardelyx (ARDX) Q3 Earnings Expected to Decline - Yahoo Finance
Ardelyx, Inc.'s (NASDAQ:ARDX) Shares Lagging The Industry But So Is The Business - Simply Wall St
Ardelyx (ARDX) Set to Announce Earnings on Thursday - MarketBeat
Ardelyx, Inc. (ARDX) Stock Price & Chart | Trade Now - Capital.com
Ardelyx, Inc. (NASDAQ:ARDX) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Ardelyx Announces Launch of Gut Matters: Discoveries and Innovations, a New Podcast for the IBS-C Patient Community - ForexTV.com
Ardelyx launches podcast for IBS-C community - Investing.com India
ARDELYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ardelyx, Inc. on Behalf of ... - The Bakersfield Californian
ARDELYX ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Ardelyx Inc Stock (ARDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):